Provider of mental health care services intended to identify and address issues in one's life and offer quality therapy.
Provider of mental health care services intended to identify and address issues in one's life and offer quality therapy.
Other Healthcare Technology Systems📍 New York, NYFounded 2020
Current Valuation
$3.0B
as of 2026-Q1
UNICORN
QL Price
$3.0B
0% vs last round
QuantLogix's current estimate for Grow Therapy, published 2026-09-27 — in line with the last disclosed round of $3.0B (2026-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$3.0B
2026-Q1
weight 0.71
Secondary market print
$3.0B
2026-06-27
weight 0.58
How this price has held up
No round has priced for Grow Therapy since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Grow Therapy, 2026-09-27 (c01edb2192d03db1).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Grow Therapy going public?
No. Grow Therapy is private and has not filed to go public. There is no S-1 on file.
What is Grow Therapy's valuation in 2026?
Grow Therapy is valued at $3.0B as of 2026-Q1, set by its Series D ($150M, Mar 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Grow Therapy filed an S-1?
No public S-1 is on file for Grow Therapy.
How much has Grow Therapy raised?
Grow Therapy has raised $328.1M in total, most recently a Series D of $150M in Mar 2026.
Is Grow Therapy publicly traded — can you buy Grow Therapy stock?
No. Grow Therapy is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Grow Therapy on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2020
HQ
New York, NY
Employees
635
Total Raised
$328.1M
Last Round
Series D — $150M (Mar 2026)
IPO Status
private
Fundraising Status
Series D · $150M · 6 mo ago
privateTotal raised $328.1M
Secondary Market
Implied price / share
$10.15
Open interest
3
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$150M
Mar 2026
—
$3.0B
Talent Signal
Hiring trend
▲ Hiring uptrend
+11% vs 2026-08
Open roles
30
via ashby
Product-build share
50%
engineering, research, product, design
Trajectory
scaling
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Executive bench growing while hiring expands: 1 senior hire (CFO); open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INSeth BressackCFO · 2026-09-12
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Counted from Grow Therapy's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health Care
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q1. Refreshed quarterly.